Overview

Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function

Status:
Terminated

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled, multi-center, sequential cohort study in subjects with congestive heart failure (CHF) and impaired renal function who are on stable furosemide treatment (³ 40 mg daily). A total of 50 subjects will be randomized to each increasing dose level of SLV320 or placebo in a sequential fashion.

Details

Lead Sponsor:

Solvay Pharmaceuticals

Collaborator:

Quintiles, Inc.

Treatments:

Furosemide